User menu

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

Bibliographic reference Hendlisz, Alain ; Golfinopoulos, Vassilis ; Deleporte, Amelie ; Paesmans, Marianne ; Mansy, Hazem El ; et. al. Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. In: BMC Cancer, Vol. 13, no.1, p. 190 (2013)
Permanent URL
  1. Parkin D. M., Bray F., Ferlay J., Pisani P., Global Cancer Statistics, 2002, 10.3322/canjclin.55.2.74
  2. American Joint Committee on Cancer (AJCC): AJCC Cancer Staging Manual. Edited by: Edge SB, Byrd DR, Carducci MA. 2009, New York: Springer, 7
  3. Wolmark N., Fisher B., Rockette H., Redmond C., Wickerham D. L., Fisher E. R., Jones J., Glass A., Lerner H., Lawrence W., Prager D., Wexler M., Evans J., Cruz A., Dimitrov N., Jochimsen P., , Postoperative Adjuvant Chemotherapy or BCG for Colon Cancer: Results From NSABP Protocol C-011, 10.1093/jnci/80.1.30
  4. André Thierry, Boni Corrado, Mounedji-Boudiaf Lamia, Navarro Matilde, Tabernero Josep, Hickish Tamas, Topham Clare, Zaninelli Marta, Clingan Philip, Bridgewater John, Tabah-Fisch Isabelle, de Gramont Aimery, Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer, 10.1056/nejmoa032709
  5. Chau I, Adjuvant therapy in colon cancer--what, when and how?, 10.1093/annonc/mdl029
  6. Lenihan DJ, Cardinale DM: Late Cardiac Effects of Cancer Treatment. J Clin Oncol. 2012, Sep 24. [Epub ahead of print]
  7. Ahles TA, Root JC, Ryan EL: Cancer- and Cancer Treatment-Associated Cognitive Change: An Update on the State of the Science. J Clin Oncol. 2012, Sep 24. [Epub ahead of print]
  8. Jim Heather S.L., Phillips Kristin M., Chait Sari, Faul Leigh Anne, Popa Mihaela A., Lee Yun-Hsiang, Hussin Mallory G., Jacobsen Paul B., Small Brent J., Meta-Analysis of Cognitive Functioning in Breast Cancer Survivors Previously Treated With Standard-Dose Chemotherapy, 10.1200/jco.2011.39.5640
  9. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB: Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction. J Clin Oncol. 2012, [Epub ahead of print]
  10. Miller A. B., Hoogstraten B., Staquet M., Winkler A., Reporting results of cancer treatment, 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>;2-6
  11. Therasse Patrick, Arbuck Susan G., Eisenhauer Elizabeth A., Wanders Jantien, Kaplan Richard S., Rubinstein Larry, Verweij Jaap, Van Glabbeke Martine, van Oosterom Allan T., Christian Michaele C., Gwyther Steve G., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, 10.1093/jnci/92.3.205
  12. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), 10.1016/j.ejca.2008.10.026
  13. Rousseau Caroline, Devillers Anne, Sagan Christine, Ferrer Ludovic, Bridji Boumédiène, Campion Loïc, Ricaud Myriam, Bourbouloux Emmanuelle, Doutriaux Isabelle, Clouet Martine, Berton-Rigaud Dominique, Bouriel Catherine, Delecroix Valérie, Garin Etienne, Rouquette Sophie, Resche Isabelle, Kerbrat Pierre, Chatal Jean François, Campone Mario, Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography, 10.1200/jco.2006.05.7406
  14. Kostakoglu Lale, Goldsmith Stanley J., Leonard John P., Christos Paul, Furman Richard R., Atasever Tamer, Chandramouly Angely, Verma Sumeet, Kothari Pratichi, Coleman Morton, FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease, 10.1002/cncr.22276
  15. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M: Impact of [18 F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High-Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol. 2012, Oct 29. [Epub ahead of print]
  16. Nahmias C., Hanna W. T., Wahl L. M., Long M. J., Hubner K. F., Townsend D. W., Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT, 10.2967/jnumed.106.038513
  17. Schaake Eva E., Kappers Ingrid, Codrington Henk E., Valdés Olmos Renato A., Teertstra Hendrik J., van Pel Renée, Burgers Jacobus A., van Tinteren Harm, Klomp Houke M., Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non–Small-Cell Lung Cancer, 10.1200/jco.2011.39.4882
  18. Ott Katja, Weber Wolfgang A., Lordick Florian, Becker Karen, Busch Raymonde, Herrmann Ken, Wieder Hinrich, Fink Ulrich, Schwaiger Markus, Siewert Jörg-Rüdiger, Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction, 10.1200/jco.2006.06.7801
  19. Lordick Florian, Ott Katja, Krause Bernd-Joachim, Weber Wolfgang A, Becker Karen, Stein Hubert J, Lorenzen Sylvie, Schuster Tibor, Wieder Hinrich, Herrmann Ken, Bredenkamp Rainer, Höfler Heinz, Fink Ulrich, Peschel Christian, Schwaiger Markus, Siewert Jörg R, PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial, 10.1016/s1470-2045(07)70244-9
  20. Meyer zum Buschenfelde C., Herrmann K., Schuster T., Geinitz H., Langer R., Becker K., Ott K., Ebert M., Zimmermann F., Friess H., Schwaiger M., Peschel C., Lordick F., Krause B. J., 18F-FDG PET-Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial, 10.2967/jnumed.110.085803
  21. de Geus-Oei L.F., van Laarhoven H. W. M., Visser E. P., Hermsen R., van Hoorn B. A., Kamm Y. J. L., Krabbe P. F. M., Corstens F. H. M., Punt C. J. A., Oyen W. J. G., Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer, 10.1093/annonc/mdm470
  22. Bystrom P., Berglund A., Garske U., Jacobsson H., Sundin A., Nygren P., Frodin J.-E., Glimelius B., Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer, 10.1093/annonc/mdn744
  23. Kim J, Choi S, Yi H, Lim J, Lee M, Hyun I, Kim C: Prediction of response to chemotherapy using sequential F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with metastatic colorectal cancer. J Clin Oncol. 2007, 25 (18S): 2536-Annual Meeting Proceedings Part I
  24. Hendlisz A., Golfinopoulos V., Garcia C., Covas A., Emonts P., Ameye L., Paesmans M., Deleporte A., Machiels G., Toussaint E., Vanderlinden B., Awada A., Piccart M., Flamen P., Serial FDG–PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy, 10.1093/annonc/mdr554
  25. Calvo Felipe A, Domper Marta, Matute Raúl, Martínez-Lázaro Raúl, Arranz José A, Desco Manuel, Álvarez Emilio, Carreras José Luis, 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation, 10.1016/j.ijrobp.2003.09.058
  26. Capirci Carlo, Rampin Lucia, Erba Paola A., Galeotti Fabrizio, Crepaldi Giorgio, Banti Elena, Gava Marcello, Fanti Stefano, Mariani Giuliano, Muzzio Pier Carlo, Rubello Domenico, Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy, 10.1007/s00259-007-0426-1
  27. Romas N, Kilpatrick NW, Ntouroupi TG: Analysis of circulating tumour cells in prostate, colorectal and ovarian cancer using robotic microscopy [abstract]. J Clin Oncol. 2008, 26: May 20 suppl; abstr 11084
  28. Meropol NJ, Cohen SJ, Iannotti N, Saidman BH, Sabbath KD, Miller MC, Doyle GV, Tissing H, Terstappen LWMM, Punt CJA: Circulating tumour cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer. J Clin Oncol. 2007, 25 (18S): 4010-ASCO Annual Meeting Proceedings Part I. 2007
  29. Cohen Steven J., Punt Cornelis J.A., Iannotti Nicholas, Saidman Bruce H., Sabbath Kert D., Gabrail Nashat Y., Picus Joel, Morse Michael, Mitchell Edith, Miller M. Craig, Doyle Gerald V., Tissing Henk, Terstappen Leon W.M.M., Meropol Neal J., Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer, 10.1200/jco.2007.15.8923
  30. Cohen Steven J., Punt Cornelis J.A., Iannotti Nicholas, Saidman Bruce H., Sabbath Kert D., Gabrail Nashat Y., Picus Joel, Morse Michael, Mitchell Edith, Miller M. Craig, Doyle Gerald V., Tissing Henk, Terstappen Leon W.M.M., Meropol Neal J., Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer, 10.1200/jco.2007.15.8923
  31. Cristofanilli Massimo, Budd G. Thomas, Ellis Matthew J., Stopeck Alison, Matera Jeri, Miller M. Craig, Reuben James M., Doyle Gerald V., Allard W. Jeffrey, Terstappen Leon W.M.M., Hayes Daniel F., Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer, 10.1056/nejmoa040766
  32. Hayes D. F., Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival, 10.1158/1078-0432.ccr-05-2821
  33. Nole F., Munzone E., Zorzino L., Minchella I., Salvatici M., Botteri E., Medici M., Verri E., Adamoli L., Rotmensz N., Goldhirsch A., Sandri M. T., Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications, 10.1093/annonc/mdm558
  34. Uen Yih-Huei, Lu Chien-Yu, Tsai Hsiang-Lin, Yu Fang-Jung, Huang Ming-Yii, Cheng Tian-Lu, Lin Shiu-Ru, Wang Jaw-Yuan, Persistent Presence of Postoperative Circulating Tumor Cells is a Poor Prognostic Factor for Patients with Stage I–III Colorectal Cancer after Curative Resection, 10.1245/s10434-008-9961-7
  35. Stratton Michael R., Campbell Peter J., Futreal P. Andrew, The cancer genome, 10.1038/nature07943
  36. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., Diaz L. A., Goodman S. N., David K. A., Juhl H., Kinzler K. W., Vogelstein B., Detection and quantification of mutations in the plasma of patients with colorectal tumors, 10.1073/pnas.0507904102
  37. Tesniere Antoine, Apetoh Lionel, Ghiringhelli Francois, Joza Nicholas, Panaretakis Theocharis, Kepp Oliver, Schlemmer Frederic, Zitvogel Laurence, Kroemer Guido, Immunogenic cancer cell death: a key-lock paradigm, 10.1016/j.coi.2008.05.007
  38. Ghiringhelli François, Menard Cedric, Puig Pierre Emmanuel, Ladoire Sylvain, Roux Stephan, Martin François, Solary Eric, Le Cesne Axel, Zitvogel Laurence, Chauffert Bruno, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients, 10.1007/s00262-006-0225-8
  39. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon J-P, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G, Immunogenic death of colon cancer cells treated with oxaliplatin, 10.1038/onc.2009.356
  40. Monzo Mariano, Moreno Isabel, Navarro Alfons, Ibeas Rafael, Artells Rosa, Gel Bernat, Martinez Francisco, Moreno Jose, Hernandez Raquel, Navarro-Vigo Marta, Single Nucleotide Polymorphisms in Nucleotide Excision Repair Genes XPA, XPD, XPG and ERCC1 in Advanced Colorectal Cancer Patients Treated with First-Line Oxaliplatin/Fluoropyrimidine, 10.1159/000113534
  41. Lecomte T., Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy, 10.1158/1078-0432.ccr-04-0169
  42. Bosch Tessa M, Meijerman Irma, Beijnen Jos H, Schellens Jan H M, Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer : , 10.2165/00003088-200645030-00003
  43. Stoehlmacher J., Association Between Glutathione S-Transferase P1, T1, and M1 Genetic Polymorphism and Survival of Patients With Metastatic Colorectal Cancer, 10.1093/jnci/94.12.936
  44. Galon J., Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, 10.1126/science.1129139
  45. Mlecnik Bernhard, Tosolini Marie, Kirilovsky Amos, Berger Anne, Bindea Gabriela, Meatchi Tchao, Bruneval Patrick, Trajanoski Zlatko, Fridman Wolf-Herman, Pagès Franck, Galon Jérôme, Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction, 10.1200/jco.2010.30.5425
  46. Pagès Franck, Berger Anne, Camus Matthieu, Sanchez-Cabo Fatima, Costes Anne, Molidor Robert, Mlecnik Bernhard, Kirilovsky Amos, Nilsson Malin, Damotte Diane, Meatchi Tchao, Bruneval Patrick, Cugnenc Paul-Henri, Trajanoski Zlatko, Fridman Wolf-Herman, Galon Jérôme, Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, 10.1056/nejmoa051424
  47. Pagès Franck, Kirilovsky Amos, Mlecnik Bernhard, Asslaber Martin, Tosolini Marie, Bindea Gabriela, Lagorce Christine, Wind Philippe, Marliot Florence, Bruneval Patrick, Zatloukal Kurt, Trajanoski Zlatko, Berger Anne, Fridman Wolf-Herman, Galon Jérôme, In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer, 10.1200/jco.2008.19.6147
  48. O'Connell M J, Mailliard J A, Kahn M J, Macdonald J S, Haller D G, Mayer R J, Wieand H S, Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer., 10.1200/jco.1997.15.1.246
  49. Laurie J A, Moertel C G, Fleming T R, Wieand H S, Leigh J E, Rubin J, McCormack G W, Gerstner J B, Krook J E, Malliard J, Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic., 10.1200/jco.1989.7.10.1447